Top ▲

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Severe combined immunodeficiency due to adenosine deaminase deficiency

Disease ID:850
Name:Severe combined immunodeficiency due to adenosine deaminase deficiency
Associated with:1 target
Synonyms
ADA-SCID | Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase
Description
ADA-SCID is an ultra-rare, inherited genetic disorder, caused adenosine deaminase (ADA) deficiency. Affected individuals experience recurrent and potentially life-threatening infections as their immune systems are severely compromised by the build up of toxic metabolites in the absence of ADA activity.
Database Links
Disease Ontology: DOID:5810
OMIM: 102700
Orphanet: ORPHA277

Targets

Adenosine deaminase
Role:  ADA-SCID is caused by a genetic deficiency in the adenosine deaminase enzyme. It is fatal if left untreated.
Drugs:  The US FDA approved an enzyme replacement therapy (ERT) for ADA-SCID in October 2018. This ERT contains the recombinant adenosine deaminase, elapegademase-lvlr and has the trade name Revcovi®.
Therapeutic use:  Elapegademase-lvlr can be administered to pediatric and adult patients.

Ligands

No ligand related data available for Severe combined immunodeficiency due to adenosine deaminase deficiency